GC Pharma partners with Speragen to develop first in class drug for a rare disease
Jul 20, 2021
South Korean biopharmaceutical firm GC Pharma has partnered with US-based biotech firm Speragen to develop a cure for a rare disease, according to the company, Tuesday. According to GC Pharma, the two companies will develop an enzyme replacement therapy for a rare disease called succinic semialdehyde dehydrogenase deficiency, which currently has no treatment. The two companies aim to start preclinical studies this year and phase 1 and 2 clinical trials during the second half of 2023. Under